{"filing":{"accession_number":"0001193125-26-386434","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"d32116d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526386434/d32116d6k.htm"},"events":[{"id":32317,"run_id":29693,"accession_number":"0001193125-26-386434","anchor_item_number":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The 6-K discloses a grant of 29,380 warrants to employees on September 8, 2026, with an exercise price of $270.09 per share and a four-year vesting schedule (25% at one year, then 1/36th monthly). This is a compensatory arrangement for named executives and employees under the company's Articles of Association, materially affecting equity incentive arrangements and shareholder dilution.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":35464,"accession_number":"0001193125-26-386434","item_number":null,"item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The 6-K discloses a grant of 29,380 warrants to employees on September 8, 2026, with an exercise price of $270.09 per share and a four-year vesting schedule (25% at one year, then 1/36th monthly). This is a compensatory arrangement for named executives and employees under the company's Articles of Association, materially affecting equity incentive arrangements and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:04:57.756769+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-09"}]}